AU2019413366B2 - Anti-CTLA-4 binding proteins and methods of use thereof - Google Patents

Anti-CTLA-4 binding proteins and methods of use thereof Download PDF

Info

Publication number
AU2019413366B2
AU2019413366B2 AU2019413366A AU2019413366A AU2019413366B2 AU 2019413366 B2 AU2019413366 B2 AU 2019413366B2 AU 2019413366 A AU2019413366 A AU 2019413366A AU 2019413366 A AU2019413366 A AU 2019413366A AU 2019413366 B2 AU2019413366 B2 AU 2019413366B2
Authority
AU
Australia
Prior art keywords
seq
antibody
ctla
cdr3
abp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019413366A
Other languages
English (en)
Other versions
AU2019413366A1 (en
Inventor
Adam Shultz Adler
Michael ASENSIO
David Scott Johnson
Yoong Wearn LIM
Rena Aviva Mizrahi
Erica Lyn STONE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gigagen Inc
Original Assignee
Gigagen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gigagen Inc filed Critical Gigagen Inc
Publication of AU2019413366A1 publication Critical patent/AU2019413366A1/en
Application granted granted Critical
Publication of AU2019413366B2 publication Critical patent/AU2019413366B2/en
Priority to AU2025223772A priority Critical patent/AU2025223772A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2019413366A 2018-12-27 2019-12-27 Anti-CTLA-4 binding proteins and methods of use thereof Active AU2019413366B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025223772A AU2025223772A1 (en) 2018-12-27 2025-08-27 Anti-CTLA-4 binding proteins and methods of use thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862785659P 2018-12-27 2018-12-27
US62/785,659 2018-12-27
PCT/US2019/068820 WO2020140084A1 (en) 2018-12-27 2019-12-27 Anti-ctla-4 binding proteins and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025223772A Division AU2025223772A1 (en) 2018-12-27 2025-08-27 Anti-CTLA-4 binding proteins and methods of use thereof

Publications (2)

Publication Number Publication Date
AU2019413366A1 AU2019413366A1 (en) 2021-08-12
AU2019413366B2 true AU2019413366B2 (en) 2025-06-05

Family

ID=71126610

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2019413366A Active AU2019413366B2 (en) 2018-12-27 2019-12-27 Anti-CTLA-4 binding proteins and methods of use thereof
AU2025223772A Pending AU2025223772A1 (en) 2018-12-27 2025-08-27 Anti-CTLA-4 binding proteins and methods of use thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025223772A Pending AU2025223772A1 (en) 2018-12-27 2025-08-27 Anti-CTLA-4 binding proteins and methods of use thereof

Country Status (12)

Country Link
US (1) US12421311B2 (https=)
EP (1) EP3902821A4 (https=)
JP (2) JP7558949B2 (https=)
KR (1) KR20210121045A (https=)
CN (2) CN119930820A (https=)
AU (2) AU2019413366B2 (https=)
BR (1) BR112021012588A2 (https=)
CA (2) CA3124961C (https=)
IL (2) IL284156B2 (https=)
MX (1) MX2021007848A (https=)
SG (1) SG11202106764YA (https=)
WO (1) WO2020140084A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3002957A1 (en) * 2015-10-23 2017-04-27 Koninklijke Nederlandse Akademie Van Wetenschappen Binding molecules that inhibit cancer growth
AU2019413366B2 (en) 2018-12-27 2025-06-05 Gigagen, Inc. Anti-CTLA-4 binding proteins and methods of use thereof
CA3184082A1 (en) * 2020-07-02 2022-01-06 David Scott Johnson Anti-ctla-4 binding proteins and methods of use thereof
JP2024502035A (ja) * 2020-12-31 2024-01-17 ノヴァロック バイオセラピューティクス， リミテッド Ｔｎｆｒ２に対する抗体およびそれの使用
WO2023279068A1 (en) * 2021-07-02 2023-01-05 Gigagen, Inc. Anti-ctla-4 binding proteins and methods of use thereof
AU2022407541A1 (en) * 2021-12-10 2024-06-13 Merck Sharp & Dohme Llc Human mesothelin binders
WO2023215560A1 (en) 2022-05-05 2023-11-09 Atoosa Corporation Tumor cell/immune cell multivalent receptor engager – bio-nanoparticle (timre-bnp)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006029219A2 (en) * 2004-09-08 2006-03-16 Ohio State University Research Foundation Human monoclonal anti-ctla4 antibodies in cancer treatment
US20130136749A1 (en) * 1999-08-24 2013-05-30 Medarex, Inc. Human CTLA-4 Antibodies And Their Uses
WO2017106372A1 (en) * 2015-12-15 2017-06-22 Oncoimmune, Inc. Chimeric and humanized anti-human ctla4 monoclonal antibodies and uses thereof
US9714290B2 (en) * 2011-03-09 2017-07-25 Antitope Limited Humanised anti CTLA-4 antibodies
WO2017194265A1 (en) * 2016-05-10 2017-11-16 Agency For Science, Technology And Research Anti-CTLA-4 Antibodies
EP3256165A2 (en) * 2015-02-13 2017-12-20 Sorrento Therapeutics, Inc. Antibody therapeutics that bind ctla4
WO2018209701A1 (en) * 2017-05-19 2018-11-22 Wuxi Biologics (Shanghai) Co., Ltd. Novel monoclonal antibodies to cytotoxic t-lymphocyte-associated protein 4 (ctla-4)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL148079A0 (en) * 1999-08-24 2002-09-12 Medarex Inc Human ctla-4 antibodies and compositions containing the same
US20110166335A1 (en) 2000-06-30 2011-07-07 Corbin David R Xenorhabdus sp. genome sequences and uses thereof
TWI320716B (en) * 2002-10-14 2010-02-21 Abbott Lab Erythropoietin receptor binding antibodies
CN104968364A (zh) 2012-12-03 2015-10-07 百时美施贵宝公司 强化免疫调变性Fc融合蛋白的抗癌活性
WO2015092394A1 (en) 2013-12-17 2015-06-25 Kymab Limited Antibodies for use in treating conditions related to specific pcsk9 variants in specific patients populations
PT3151921T (pt) * 2014-06-06 2019-11-21 Bristol Myers Squibb Co Anticorpos contra recetor do fator de necrose tumoral induzido por glicocorticoide e utilizações dos mesmos
TN2017000440A1 (en) 2015-04-17 2019-04-12 Bristol Myers Squibb Co Compositions comprising a combination of an anti-pd-1 antibody and another antibody
MA44594B1 (fr) * 2015-05-29 2020-09-30 Memorial Sloan Kettering Cancer Center Anticorps anti-ctla-4 et méthodes d'utilisation de ceux-ci
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
NL2017270B1 (en) 2016-08-02 2018-02-09 Aduro Biotech Holdings Europe B V New anti-hCTLA-4 antibodies
CN120173123A (zh) 2017-02-27 2025-06-20 蜻蜓疗法股份有限公司 靶向caix、ano1、间皮素、trop2、cea或紧密连接蛋白-18.2的多特异性结合蛋白
TWI799432B (zh) 2017-07-27 2023-04-21 美商再生元醫藥公司 抗ctla-4抗體及其用途
AU2019413366B2 (en) 2018-12-27 2025-06-05 Gigagen, Inc. Anti-CTLA-4 binding proteins and methods of use thereof
EP3914355A1 (en) 2019-01-21 2021-12-01 Sanofi Therapeutic rna and anti-pd1 antibodies for advanced stage solid tumor cancers
CA3184082A1 (en) 2020-07-02 2022-01-06 David Scott Johnson Anti-ctla-4 binding proteins and methods of use thereof

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130136749A1 (en) * 1999-08-24 2013-05-30 Medarex, Inc. Human CTLA-4 Antibodies And Their Uses
WO2006029219A2 (en) * 2004-09-08 2006-03-16 Ohio State University Research Foundation Human monoclonal anti-ctla4 antibodies in cancer treatment
US9714290B2 (en) * 2011-03-09 2017-07-25 Antitope Limited Humanised anti CTLA-4 antibodies
EP3256165A2 (en) * 2015-02-13 2017-12-20 Sorrento Therapeutics, Inc. Antibody therapeutics that bind ctla4
WO2017106372A1 (en) * 2015-12-15 2017-06-22 Oncoimmune, Inc. Chimeric and humanized anti-human ctla4 monoclonal antibodies and uses thereof
WO2017194265A1 (en) * 2016-05-10 2017-11-16 Agency For Science, Technology And Research Anti-CTLA-4 Antibodies
WO2018209701A1 (en) * 2017-05-19 2018-11-22 Wuxi Biologics (Shanghai) Co., Ltd. Novel monoclonal antibodies to cytotoxic t-lymphocyte-associated protein 4 (ctla-4)

Also Published As

Publication number Publication date
JP7558949B2 (ja) 2024-10-01
JP2022516071A (ja) 2022-02-24
AU2019413366A1 (en) 2021-08-12
IL284156B1 (en) 2024-12-01
WO2020140084A1 (en) 2020-07-02
IL316757A (en) 2025-01-01
IL284156A (en) 2021-08-31
MX2021007848A (es) 2021-10-26
IL284156B2 (en) 2025-04-01
US20220064303A1 (en) 2022-03-03
JP7745669B2 (ja) 2025-09-29
CN114008071A (zh) 2022-02-01
AU2025223772A1 (en) 2025-09-18
KR20210121045A (ko) 2021-10-07
CA3124961C (en) 2025-11-25
EP3902821A4 (en) 2022-11-30
JP2025128343A (ja) 2025-09-02
EP3902821A1 (en) 2021-11-03
CN119930820A (zh) 2025-05-06
US12421311B2 (en) 2025-09-23
BR112021012588A2 (pt) 2021-09-08
SG11202106764YA (en) 2021-07-29
CN114008071B (zh) 2025-01-21
CA3249127A1 (en) 2026-03-02
CA3124961A1 (en) 2020-07-02
JP2024042072A (ja) 2024-03-27

Similar Documents

Publication Publication Date Title
AU2019413366B2 (en) Anti-CTLA-4 binding proteins and methods of use thereof
US20220064302A1 (en) Anti-PD-1 Binding Proteins and Methods of Use Thereof
WO2020140094A1 (en) Anti-b7-h3 binding proteins and methods of use thereof
JP7783840B2 (ja) 抗ｃｔｌａ－４結合タンパク質及びその使用方法
WO2020142626A1 (en) Anti-ox40 binding proteins and methods of use thereof
WO2022006555A2 (en) BISPECIFIC ANTIGEN BINDING PROTEINS TARGETING PD-L1 AND TGF-β AND METHODS OF USE
US20220056137A1 (en) Anti-PD-L1 Binding Proteins and Methods of Use Thereof
WO2020140070A1 (en) Anti-b7-h4 binding proteins and methods of use thereof
JP7854093B2 (ja) 抗ｃｔｌａ－４結合タンパク質およびその使用方法

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)